17 patents
Utility
Synthesis of uniformly defined molecular weight mannosylated dextrans and derivatives thereof
2 Jan 24
Disclosed herein is method for conjugating a metal chelating agent to a functionalized dextran by reacting a chelator with an aminated dextran backbone, where the chelator comprises a one, and only one, derivatized carboxylic acid group to form a chelator-dextran complex.
Jeffrey Arnold, David A. Ralph
Filed: 8 Jul 21
Utility
Altering net charge on mannosylated dextrans to maximize target tissue uptake and off target competitive blocking
5 Dec 23
Provided are compounds, compositions, methods, and kits for increasing target specificity of a mannosylated carbohydrate polymeric therapeutic or diagnostic compound to reduce or eliminate localization of the mannosylated carbohydrate polymeric therapeutic or diagnostic compound to off-target sites.
David A. Ralph, Jeffrey Scott Arnold
Filed: 3 Feb 23
Utility
CD206 Targeted Drug Delivery Vehicles Carrying Novel Bisphosphonate Drug Payloads Via a Degradable Linker
23 Nov 23
Provided are novel compounds containing a polymeric carbohydrate backbone, one or more mannose-binding C-type lectin receptor targeting moieties, and a nitrogenous bisphosphonate compound coupled to the backbone via a thiol-maleimide conjugation, in addition to pharmaceutical compositions, methods of synthesizing, and methods of use.
David A. Ralph, Jeffrey Scott Arnold
Filed: 19 May 23
Utility
Competitive Self-Blocking with Unlabeled Manocept Imaging Agents
28 Sep 23
Disclosed is a method for increased target specificity of a mannosylated carbohydrate polymeric therapeutic and/or diagnostic compound by administering a blocking composition comprising a backbone and one or more C-type lectin receptor targeting moieties attached thereto with an effective amount of the mannosylated dextran therapeutic and/or diagnostic compound.
David A. Ralph
Filed: 24 Mar 23
Utility
Altering Net Charge on Mannosylated Dextrans to Maximize Target Tissue Uptake and Off Target Competitive Blocking
10 Aug 23
Provided are compounds, compositions, methods, and kits for increasing target specificity of a mannosylated carbohydrate polymeric therapeutic or diagnostic compound to reduce or eliminate localization of the mannosylated carbohydrate polymeric therapeutic or diagnostic compound to off-target sites.
David A. Ralph, Jeffrey Scott Arnold
Filed: 3 Feb 23
Utility
Compositions and Methods for Altering Macrophage Phenotype
13 Jul 23
Disclosed are methods and compositions for repolarizing a tumor associated macrophage (TAM) from M2 to M1 comprising administering to a subject in need thereof an effective dose of a compound comprising a dextran backbone and one or more CD206 targeting moieties conjugated thereto.
David A. Ralph
Filed: 27 Feb 23
Utility
Methods for the Conjugation of Anthracyclines to Carbohydrate Polymeric Carriers
6 Jul 23
Methods, compounds, and compositions of conjugating anthracyclines to a carbohydrate polymer backbone via click chemistry are provided.
David A. Ralph, Jeffrey Arnold
Filed: 29 Dec 22
Utility
Compositions and Methods for the Treatment of Rheumatoid Arthritis
9 Mar 23
Disclosed herein are methods of treating a subject with rheumatoid arthritis (RA) and methods of predicting the subject's likelihood of responding to a new RA therapy.
David A. Ralph, Michael Rosol
Filed: 19 Aug 22
Utility
Compositions and methods for altering macrophage phenotype
28 Feb 23
Disclosed are methods and compositions for repolarizing a tumor associated macrophage (TAM) from M2 to M1 comprising administering to a subject in need thereof an effective dose of a compound comprising a dextran backbone and one or more CD206 targeting moieties conjugated thereto.
David A. Ralph
Filed: 27 Mar 20
Utility
Dual Balloon Catheter and Related Methods for Treatment of Heart Failure
30 Jun 22
A dual balloon catheter having two independently inflatable balloons that provides complete or intermittent synchronous occlusion of blood vessels (such as the contralateral iliac veins, for example) via the balloons, which can be used for the purpose of decreasing the pressure in the inferior vena cava, which results in decongestion of the kidneys, liver/splanchnic compartment, lymphatic system, and the heart.
Wassef Karrowni, Mirna Karouni
Filed: 30 Dec 21
Utility
Synthesis of Uniformly Defined Molecular Weight Mannosylated Dextrans and Derivatives Thereof
13 Jan 22
Disclosed herein is method for conjugating a metal chelating agent to a functionalized dextran by reacting a chelator with an aminated dextran backbone, where the chelator comprises a one, and only one, derivatized carboxylic acid group to form a chelator-dextran complex.
Jeffery Arnold, David A. Ralph
Filed: 8 Jul 21
Utility
Compounds and Methods for Diagnosis and Treatment of Viral Infections
4 Nov 21
Compositions and methods of using these compositions that can include a targeting moiety and a therapeutic agent are described herein.
Frederick O. Cope, David A. Ralph
Filed: 18 May 21
Utility
Compositions and Related Methods for Blocking Off-target Localization of Mannosylated Dextrans and Other CD206 Ligands
20 May 21
Disclosed is a method for increase target specificity of a mannosylated dextran therapeutic or diagnostic compound by administering at least a blocking composition comprising a backbone and one or more CD206 targeting moieties attached thereto; administering an effective amount of the mannosylated dextran therapeutic or diagnostic compound comprising a dextran backbone and one or more CD206 targeting moieties and one or more therapeutic agents attached thereto.
David A. Ralph, Jeffery Arnold
Filed: 30 Sep 20
Utility
Compounds and methods for diagnosis and treatment of viral infections
18 May 21
Compositions and methods of using these compositions that can include a targeting moiety and a therapeutic agent are described herein.
Frederick O. Cope, David A. Ralph
Filed: 10 Oct 17
Utility
Compositions and Related Methods for the Ablation of M2 Macrophages and Myeloid Derived Suppressor Cells
25 Feb 21
Compositions and methods for ablating CD206 expressing macrophages and/or CD206 expressing myeloid derived suppressor cells (MDSCs) are disclosed.
David A. Ralph
Filed: 19 Aug 20
Utility
Compositions and Methods for Altering Macrophage Phenotype
30 Sep 20
Disclosed are methods and compositions for repolarizing a tumor associated macrophage (TAM) from M2 to M1 comprising administering to a subject in need thereof an effective dose of a compound comprising a dextran backbone and one or more CD206 targeting moieties conjugated thereto.
David A. Ralph
Filed: 26 Mar 20
Utility
Compositions and Methods for Assessing Macrophage Mediated Pathology
29 Jul 20
Compositions and methods are disclosed for assessing macrophage involvement in the inflammation of one or more joints of a subject.
David A. Ralph, Michael Rosol, Ahmad Ismail, Allison Kissling, Frederick O. Cope, Bonnie Chandler Abbruzzese
Filed: 26 Jan 20
- Prev
- 1
- Next
Patents are sorted by USPTO publication date, most recent first